L. Albiges, M. Salem, B. Rini, and B. Escudier, Vascular Endothelial Growth Factor???Targeted Therapies in Advanced Renal Cell Carcinoma, Hematology/Oncology Clinics of North America, vol.25, issue.4, pp.813-833, 2011.
DOI : 10.1016/j.hoc.2011.04.006

B. Bochner, R. Cote, N. Weidner, S. Groshen, S. Chen et al., Angiogenesis in Bladder Cancer: Relationship Between Microvessel Density and Tumor Prognosis, JNCI Journal of the National Cancer Institute, vol.87, issue.21, pp.1603-1612, 1995.
DOI : 10.1093/jnci/87.21.1603

B. Bussolati, S. Bruno, C. Grange, U. Ferrando, and G. Camussi, Identification of a tumor-initiating stem cell population in human renal carcinomas, The FASEB Journal, vol.22, issue.10, pp.3696-3705, 2008.
DOI : 10.1096/fj.08-102590

H. Cohen and F. Mcgovern, Renal-Cell Carcinoma, New England Journal of Medicine, vol.353, issue.23, pp.2477-2490, 2005.
DOI : 10.1056/NEJMra043172

N. Dallas, S. Samuel, L. Xia, F. Fan, M. Gray et al., Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy, Clinical Cancer Research, vol.14, issue.7, pp.1931-1937, 2008.
DOI : 10.1158/1078-0432.CCR-07-4478

B. Delahunt, P. Bethwaite, and A. Thornton, Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma, BJU International, vol.80, issue.3, pp.401-404, 1997.
DOI : 10.1046/j.1464-410X.1997.00374.x

R. Derynck and X. Feng, TGF-beta receptor signaling, Biochim Biophys Acta, vol.1333, issue.2, pp.105-150, 1997.

W. Dubinski, M. Gabril, V. Iakovlev, A. Scorilas, Y. Youssef et al., Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis, Human Pathology, vol.43, issue.7, pp.1037-1043, 2012.
DOI : 10.1016/j.humpath.2011.08.012

S. Duff, C. Li, J. Garland, and S. Kumar, CD105 is important for angiogenesis: evidence and potential applications, The FASEB Journal, vol.17, issue.9, pp.984-992, 2003.
DOI : 10.1096/fj.02-0634rev

T. Eisen, C. Sternberg, C. Robert, P. Mulders, L. Pyle et al., Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies, JNCI Journal of the National Cancer Institute, vol.104, issue.2, pp.93-113, 2012.
DOI : 10.1093/jnci/djr511

R. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. Van-poppel et al., Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis, The Journal of Urology, vol.171, issue.3, pp.1071-1076, 2004.
DOI : 10.1097/01.ju.0000110610.61545.ae

S. Fuhrman, L. Lasky, and C. Limas, Prognostic significance of morphologic parameters in renal cell carcinoma, The American Journal of Surgical Pathology, vol.6, issue.7, pp.655-663, 1982.
DOI : 10.1097/00000478-198210000-00007

A. Gougos and M. Letarte, Primary structure of endoglin, an RGDcontaining glycoprotein of human endothelial cells, J Biol Chem, vol.265, issue.15, pp.8361-8364, 1990.

C. Grange, M. Tapparo, F. Collino, L. Vitillo, C. Damasco et al., Microvesicles Released from Human Renal Cancer Stem Cells Stimulate Angiogenesis and Formation of Lung Premetastatic Niche, Cancer Research, vol.71, issue.15, pp.71-5346, 2011.
DOI : 10.1158/0008-5472.CAN-11-0241

P. Hermann, S. Bhaskar, M. Cioffi, and C. Heeschen, Cancer stem cells in solid tumors, Seminars in Cancer Biology, vol.20, issue.2, pp.77-84, 2010.
DOI : 10.1016/j.semcancer.2010.03.004

P. Kumar, J. Wang, and C. Bernabeu, EDITORIAL. CD105 AND ANGIOGENESIS, The Journal of Pathology, vol.8, issue.4, pp.363-366, 1996.
DOI : 10.1002/(SICI)1096-9896(199604)178:4<363::AID-PATH491>3.0.CO;2-8

C. Li, B. Guo, P. Wilson, A. Stewart, G. Byrne et al., Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer, International Journal of Cancer, vol.76, issue.2, pp.122-126, 2000.
DOI : 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M

D. Minardi, G. Lucarini, R. Mazzucchelli, G. Milanese, D. Natali et al., PROGNOSTIC ROLE OF FUHRMAN GRADE AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN pT1a CLEAR CELL CARCINOMA IN PARTIAL NEPHRECTOMY SPECIMENS, The Journal of Urology, vol.174, issue.4, pp.1208-1212, 2005.
DOI : 10.1097/01.ju.0000173078.57871.2d

R. Minhajat, D. Mori, F. Yamasaki, Y. Sugita, T. Satoh et al., Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers, Pathology International, vol.14, issue.12, pp.717-723, 2006.
DOI : 10.1007/s00262-006-0155-5

L. Rosen, H. Hurwitz, M. Wong, J. Goldman, D. Mendelson et al., A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer, Clinical Cancer Research, vol.18, issue.17, pp.4820-4829, 2012.
DOI : 10.1158/1078-0432.CCR-12-0098

J. Sandlund, Y. Hedberg, A. Bergh, K. Grankvist, B. Ljungberg et al., Endoglin (CD105) expression in human renal cell carcinoma, BJU International, vol.80, issue.4, pp.706-710, 2006.
DOI : 10.1111/j.1464-410X.2004.04605.x

B. Seon, F. Matsuno, Y. Haruta, M. Kondo, and M. Barcos, Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin, Clin Cancer Res, vol.3, issue.7, pp.1031-1044, 1997.

S. Sudarshan, J. Karam, J. Brugarolas, R. Thompson, R. Uzzo et al., Metabolism of Kidney Cancer: From the Lab to Clinical Practice, European Urology, vol.63, issue.2, pp.244-251, 2013.
DOI : 10.1016/j.eururo.2012.09.054

N. Takahashi, A. Haba, F. Matsuno, and B. Seon, Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide, Cancer Res, issue.21, pp.61-7846, 2001.

P. Vermeulen, G. Gasparini, S. Fox, T. M. Martin, L. Mcculloch et al., Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation, European Journal of Cancer, vol.32, issue.14, pp.2474-2484, 1996.
DOI : 10.1016/S0959-8049(96)00379-6

A. Volpe and J. Patard, Prognostic factors in renal cell carcinoma, World Journal of Urology, vol.27, issue.3, pp.319-327, 2010.
DOI : 10.1007/s00345-010-0540-8

URL : https://hal.archives-ouvertes.fr/inserm-00472418

N. Weidner, J. Semple, W. Welch, and J. Folkman, Tumor Angiogenesis and Metastasis ??? Correlation in Invasive Breast Carcinoma, New England Journal of Medicine, vol.324, issue.1, pp.1-8, 1991.
DOI : 10.1056/NEJM199101033240101

P. Wikstrom, I. Lissbrant, P. Stattin, L. Egevad, and A. Bergh, Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer, The Prostate, vol.97, issue.4, pp.268-275, 2002.
DOI : 10.1002/pros.10083

H. Yagasaki, N. Kawata, Y. Takimoto, and N. Nemoto, Histopathological analysis of angiogenic factors in renal cell carcinoma, International Journal of Urology, vol.5, issue.4, pp.220-227, 2003.
DOI : 10.1016/S0303-7207(01)00709-2